Table 3.
Global changes in histone modifications in hypoxia. Publications showing global changes in histone methylation and acetylation in hypoxia across various cell types, oxygen levels, and duration of hypoxia. Up arrows indicate global induction of specific PTMs, down arrows indicate global reduction, and dashes indicate no significant change. ac indicates acetylation at that specific histone subunit and lysine residue, while me1, me2, and me3 indicate mono-, di-, and tri- methylation, respectively.
| Global Changes to Histone Modifications in Hypoxia | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reference | Cell Line(s) | % O2 | Time (h) | H2AK5 | H3K4 | H3K9 | H3K14 | H3K16 | H3K27 | H3K36 | H3K79 | H4 | H4K5 | H4K12 | H4R3 | |||||||||
| ac | ac | me1 | me2 | me3 | ac | me1 | me2 | me3 | ac | ac | ac | me2 | me3 | me2 | me3 | me2 | ac | ac | ac | me2 | ||||
| Costa, 2005 [86] | A549 | 0.5 | 1.5–9 | ↓ | ↓ | ↑ | ↑ | ↓ | ||||||||||||||||
| Chen, 2006 [87] | A549, HOS, HEK293, MES | 0.5 | 1.5–24 | ↓ | ↓ | ↑ | ↑ | |||||||||||||||||
| Islam, 2006 [89] | Fetal lung type II | 2 | 24 | ↓ | ↑ | |||||||||||||||||||
| Johnson, 2008 [90] | Hepa 1-6 | 0.2 | 48 | ↑ | ↑ | ↑ | ↓ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | |||||||||||
| Xia, 2009 [29] | HepG2 | 0.5–5 | 24 | ↑ | ↑ | ↑ | ↑ | |||||||||||||||||
| Zhou, 2010 [99] | Beas-2B, A549 | 1 | 6–48 | ↑ | ||||||||||||||||||||
| Tausendschon, 2011 [96] | RAW254.7 | 1–8 | 24 | ↑ | ↑ | ↑ | ||||||||||||||||||
| Wu, 2011 [97] | FADU, MCF-7 | 1 | 18 | ↓ | ↓ | ↑ | ↑ | - | - | ↓ | ↓ | |||||||||||||
| Olcina, 2013 [101] | RKO | <0.1, 2 | 6 to 18 | ↑ | ↑ | - | ||||||||||||||||||
| Watson, 2014 [77] | PwR-1E | 10% × 7wks, 3% × 4wks, then 1% × 3wks | ↓ | |||||||||||||||||||||
| Osumek, 2014 [94] | McA-RH777 | 1, 5 | 24 or 48 | ↑ | ||||||||||||||||||||
| Dmitriev, 2015 [100] | PC12 | 0 & no glucose | 1 to 9 | ↓ | ||||||||||||||||||||
| Olcina, 2016 [93] | RKO | <0.1, 2 | 6–48 | ↑ | ||||||||||||||||||||
| Prickaerts, 2016 [95] | MCF-7 | <0.2 | 8 or 24 | ↑ | ↑ | |||||||||||||||||||
| Dobrynin, 2017 [88] | RKO | 0.1, 2 | 24 | ↑ | ↑ | |||||||||||||||||||
| Hancock, 2017 [55] | U2OS | 0.1–5 | 24 | - | ↑ | ↑ | ↑ | |||||||||||||||||
| Lee, 2017 [91] | hADSC | <0.5, 1, 2 | 24 or 48 | ↑ | ↑ | ↑ | ||||||||||||||||||
| Batie, 2019 [66] | HeLa, HFF | 1 | 0.5–24 | ↑ | ↑ | ↑ | ↑ | ↑ | ||||||||||||||||
| Chakraborty, 2019 [56] | mHepa-1 c4 | 5 | 96 | ↑ | ↑ | |||||||||||||||||||
| Li, 2020 [92] | CHP134,SMS- KCNR, MEF |
0.5 | 6 or 24 | ↓ | ↑ | ↓ | ↑ | |||||||||||||||||